ORLANDO, Fla., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB), based in Orlando, FL, focused on pharmaceuticals, today announced that Thomas K. Equels, M.S. J.D., Chief Executive Officer, was interviewed on CEOLIVE.TV on January 2nd, 2018.

The interview can be viewed at:

http://www.ceolive.tv/hemispherx-heb-going-after-multi-billion-dollar-immuno-oncology-market/

About Hemispherx Biopharma, Inc.

Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders.

Hemispherx's flagship products include Alferon N Injection® and the experimental therapeutics Ampligen®.  Ampligen® is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including Chronic Fatigue Syndrome. Hemispherx's platform technology includes components for potential treatment of various severely debilitating and life threatening diseases. Because Ampligen® is experimental in nature, they are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials.

The FDA approval of Alferon N Injection® is limited to the treatment of refractory or recurrent external genital warts in patients 18 years of age or older. The Company's Alferon® N approval in Argentina includes the use of Alferon N Injection® (under the brand name "Naturaferon") for use in any patients who fail, or become intolerant to recombinant interferon, including patients with chronic active hepatitis C infection.

The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products.

About CEOLIVE.TV

CEOLIVE.TV is an online investor media and news resource featuring interviews and commentary with top executives from U.S. publicly traded companies.

Forward Looking Statement

Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties.  For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.  In addition to the risk factors identified from time to time in our reports filed with the Securities and Exchange Commission, no assurance can be given that Ampligen® will prove effective in the treatment of pancreatic cancer or any other additional indications or that additional testing will confirm that it is effective when administered intranasally. Moreover, conducting such studies will require Hemispherx to obtain additional financing and no assurance can be given that such funding will be available.   While Hemispherx had begun to generate revenues from Ampligen®, no assurance can be given that revenues will continue or grow.    Any forward-looking statements set forth in this press release speak only as of the date of this press release.  We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.hemispherx.net. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

CONTACT

Hemispherx Biopharma
Phone Number: 800-778-4042
Email: IR@hemispherx.net